Recruiting

Dopamine vs. Norepinephrine

Sponsor:

Mount Sinai Hospital, Canada

Code:

NCT05347238

Conditions

Late-Onset Neonatal Sepsis

Extreme Prematurity

Neonatal Hypotension

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

Dopamine

Norepinephrine

Study Details

Brief summary:

Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring >48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices.

Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS.

Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS.

Hypothesis: Primary treatment with NE will be associated with a lower mortality

Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved:

Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response

Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

Conditions

Late-Onset Neonatal Sepsis

Extreme Prematurity

Neonatal Hypotension

Study ID

NCT05347238

Start date

Feb 6, 2023

Status verified date

Jul, 2025

Completion date

Mar 31, 2027

Anticipated

Primary completion date

Jun 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • ≤32 weeks gestational age and > 48 hours of life
  • Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)

Exclusion Criteria:

  • Known chromosomal or genetic anomalies
  • Receiving primary therapy with agents other than Dopamine or Norepinephrine

Study Design

Enrollment

550 participants

Anticipated

Interventions and Outcome Measures

Arms

Dopamine Units

Units who have standardized their practice with the use of Dopamine as a first line agent.

Norepinephrine Units

Units who have standardized their practice with the use of Norepinephrine as a first line agent.

Interventions

Dopamine

Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.

Norepinephrine

Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

Primary outcome measure

  • All cause in-hospital mortality [ Time Frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth ]

Central Contacts and Locations

Central contacts

Locations

Dayton Children's Hospital

Recruiting

Dayton, Ohio, United States, 45404

Methodist Healthcare

Recruiting

San Antonio, Texas, United States, 78229

Foothill's Medical Centre

Recruiting

Calgary, Alberta, Canada

Principal Investigator:

Amuchou Soraisham

BC Women's Hospital

Recruiting

Vancouver, British Columbia, Canada

Principal Investigator:

Michael Castaldo

Victoria General Hospital

Recruiting

Victoria, British Columbia, Canada, V8Z 6R5

Contacts

Winnipeg Health Sciences Centre

Recruiting

Winnipeg, Manitoba, Canada

Principal Investigator:

Deepak Louis

IWK Health Centre

Recruiting

Halifax, Nova Scotia, Canada

Principal Investigator:

Walid El Naggar

McMaster Children's Hospital

Recruiting

Hamilton, Ontario, Canada

Principal Investigator:

Amneet Sidhu

London Health Sciences Centre

Recruiting

London, Ontario, Canada

Principal Investigator:

Soume Bhattacharya

Children's Hospital of Eastern Ontario

Recruiting

Ottawa, Ontario, Canada

Principal Investigator:

Laurent Renesme

Hospital for Sick Children

Recruiting

Toronto, Ontario, Canada

Principal Investigator:

Bonny Jasani

Mount Sinai Hospital

Recruiting

Toronto, Ontario, Canada

Contacts

Principal Investigator:

Amish Jain

Sunnybrook Health Sciences Centre

Recruiting

Toronto, Ontario, Canada

Contacts

Stephanie Fevrier, MSc

stephanie.fevrier@sunnybrook.ca

Principal Investigator:

Dany Weisz

Windsor Regional Hospital

Recruiting

Windsor, Ontario, Canada

Principal Investigator:

Sajit Augustine

CHU Sainte- Justine

Recruiting

Montreal, Quebec, Canada

Principal Investigator:

Anie Lapointe

Jewish General Hospital

Recruiting

Montreal, Quebec, Canada

Principal Investigator:

Nina Nouraeyan

Montreal Children's Hospital

Recruiting

Montreal, Quebec, Canada

Principal Investigator:

Gabriel Altit

More Information

Sponsor

Mount Sinai Hospital, Canada

Last update posted

Jul 8, 2025

Last verified

Jul, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Mount Sinai Hospital, Canada on 2025-07-08.